Which treatment is considered for Guillain-Barre syndrome?

In the management of Guillain-Barré syndrome (GBS), treatment primarily focuses on reducing the severity and duration of the illness. Intravenous immunoglobulin (IVIG) and plasmapheresis are the two most effective treatments for GBS.

IVIG works by providing passive immunity and modulating the immune response, which helps to decrease the severity of the peripheral nerve damage caused by the body's immune system mistakenly attacking its own nerves. Plasmapheresis involves the removal of antibodies from the bloodstream, directly targeting the immune factors that contribute to nerve damage.

Both treatments have been shown to speed up recovery and reduce the risk of long-term disability in individuals with GBS. Clinical guidelines recommend either IVIG or plasmapheresis, based on factors such as the severity of the condition and the patient's specific situation.

Corticosteroids are not effective in treating GBS and are generally avoided due to their lack of benefit and potential to worsen the condition. Aspirin and antivirals do not play any role in the treatment of GBS, as the underlying issue is an autoimmune attack rather than a viral infection that requires antiviral therapy or standard symptomatic treatment like aspirin.